Pharmaceuticals · NYSE: NVS
Novartis earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 3 Feb 2027
Latest: Q3 2026
Novartis won FDA approval for Rhapsido in a second disease and posted positive remibrutinib multiple sclerosis data, lifting Rhapsido's peak sales target to USD 4bn+.
Priority brands including Kisqali, Kesimpta, Scemblix and Leqvio grew fast enough to more than offset generic erosion, mainly Entresto in the US. Rhapsido, the new oral treatment for chronic spontaneous urticaria (CSU), has treated over 15,000 patients in the US and won FDA approval in symptomatic dermographism. Pluvicto gained US and China approval in earlier-stage prostate cancer, and remibrutinib succeeded in two Phase III multiple sclerosis trials.
Quarters
KPI history
20-F filings
- 4 Feb 202620-F for the period ended 31 Dec 2025SEC ↗
- 31 Jan 202520-F for the period ended 31 Dec 2024SEC ↗
- 31 Jan 202420-F for the period ended 31 Dec 2023SEC ↗
- 1 Feb 202320-F for the period ended 31 Dec 2022SEC ↗
- 2 Feb 202220-F for the period ended 31 Dec 2021SEC ↗
- 26 Jan 202120-F for the period ended 31 Dec 2020SEC ↗
- 29 Jan 202020-F for the period ended 31 Dec 2019SEC ↗
- 30 Jan 201920-F for the period ended 31 Dec 2018SEC ↗